Low-dose aspirin for primary and secondary prevention of cardiovascular events in Denmark 1998–2018

Abstract Randomised controlled trials have shown a neutral or even unfavourable risk–benefit balance of aspirin for primary prevention of cardiovascular events. Using Danish nationwide registries, we investigated aspirin use and associated risks during the past two decades (1998–2018). We linked ind...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mikkel B. Christensen, Espen Jimenez-Solem, Martin. T. Ernst, Morten Schmidt, Anton Pottegård, Erik L. Grove
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/b2be06933ec84314ab22e613f81050c2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b2be06933ec84314ab22e613f81050c2
record_format	dspace
spelling	oai:doaj.org-article:b2be06933ec84314ab22e613f81050c22021-12-02T16:32:08ZLow-dose aspirin for primary and secondary prevention of cardiovascular events in Denmark 1998–201810.1038/s41598-021-93179-82045-2322https://doaj.org/article/b2be06933ec84314ab22e613f81050c22021-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-93179-8https://doaj.org/toc/2045-2322Abstract Randomised controlled trials have shown a neutral or even unfavourable risk–benefit balance of aspirin for primary prevention of cardiovascular events. Using Danish nationwide registries, we investigated aspirin use and associated risks during the past two decades (1998–2018). We linked individual patient data on repeated aspirin redemptions with registered hospital ICD-10 diagnoses of atherosclerotic cardiovascular disease and bleedings. The prevalence of aspirin use among 1.1 million Danish adults fluctuated over the 20-year study period peaking in 2008 with 8.5% (5.4% primary prevention) and dropping to 5.1% (3.1% primary prevention) in 2018. Aspirin use showed strong age dependency, and 21% of individuals > 80 years were treated with aspirin for primary prevention in 2018. Medication adding to bleeding risk was used concurrently by 21% of all aspirin users in 2018. The incidence of major bleedings were similar with primary and secondary prevention aspirin use and highest in elderly (2 per 100 patient years among individuals > 80 years in 2018). In conclusion, low-dose aspirin use for primary prevention of cardiovascular events remains prevalent. The widespread use of aspirin, especially among older adults, and substantial concomitant use of medications adding to bleeding risk warrant increased focus on discontinuation of inappropriate aspirin use.Mikkel B. ChristensenEspen Jimenez-SolemMartin. T. ErnstMorten SchmidtAnton PottegårdErik L. GroveNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Mikkel B. Christensen Espen Jimenez-Solem Martin. T. Ernst Morten Schmidt Anton Pottegård Erik L. Grove Low-dose aspirin for primary and secondary prevention of cardiovascular events in Denmark 1998–2018
description	Abstract Randomised controlled trials have shown a neutral or even unfavourable risk–benefit balance of aspirin for primary prevention of cardiovascular events. Using Danish nationwide registries, we investigated aspirin use and associated risks during the past two decades (1998–2018). We linked individual patient data on repeated aspirin redemptions with registered hospital ICD-10 diagnoses of atherosclerotic cardiovascular disease and bleedings. The prevalence of aspirin use among 1.1 million Danish adults fluctuated over the 20-year study period peaking in 2008 with 8.5% (5.4% primary prevention) and dropping to 5.1% (3.1% primary prevention) in 2018. Aspirin use showed strong age dependency, and 21% of individuals > 80 years were treated with aspirin for primary prevention in 2018. Medication adding to bleeding risk was used concurrently by 21% of all aspirin users in 2018. The incidence of major bleedings were similar with primary and secondary prevention aspirin use and highest in elderly (2 per 100 patient years among individuals > 80 years in 2018). In conclusion, low-dose aspirin use for primary prevention of cardiovascular events remains prevalent. The widespread use of aspirin, especially among older adults, and substantial concomitant use of medications adding to bleeding risk warrant increased focus on discontinuation of inappropriate aspirin use.
format	article
author	Mikkel B. Christensen Espen Jimenez-Solem Martin. T. Ernst Morten Schmidt Anton Pottegård Erik L. Grove
author_facet	Mikkel B. Christensen Espen Jimenez-Solem Martin. T. Ernst Morten Schmidt Anton Pottegård Erik L. Grove
author_sort	Mikkel B. Christensen
title	Low-dose aspirin for primary and secondary prevention of cardiovascular events in Denmark 1998–2018
title_short	Low-dose aspirin for primary and secondary prevention of cardiovascular events in Denmark 1998–2018
title_full	Low-dose aspirin for primary and secondary prevention of cardiovascular events in Denmark 1998–2018
title_fullStr	Low-dose aspirin for primary and secondary prevention of cardiovascular events in Denmark 1998–2018
title_full_unstemmed	Low-dose aspirin for primary and secondary prevention of cardiovascular events in Denmark 1998–2018
title_sort	low-dose aspirin for primary and secondary prevention of cardiovascular events in denmark 1998–2018
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/b2be06933ec84314ab22e613f81050c2
work_keys_str_mv	AT mikkelbchristensen lowdoseaspirinforprimaryandsecondarypreventionofcardiovasculareventsindenmark19982018 AT espenjimenezsolem lowdoseaspirinforprimaryandsecondarypreventionofcardiovasculareventsindenmark19982018 AT martinternst lowdoseaspirinforprimaryandsecondarypreventionofcardiovasculareventsindenmark19982018 AT mortenschmidt lowdoseaspirinforprimaryandsecondarypreventionofcardiovasculareventsindenmark19982018 AT antonpottegard lowdoseaspirinforprimaryandsecondarypreventionofcardiovasculareventsindenmark19982018 AT eriklgrove lowdoseaspirinforprimaryandsecondarypreventionofcardiovasculareventsindenmark19982018
_version_	1718383828902346752

Low-dose aspirin for primary and secondary prevention of cardiovascular events in Denmark 1998–2018

Ejemplares similares